Performance of capecitabine in novel combination therapies in colorectal cancer
Colorectal cancer is one of the most common cancers throughout the world, and no
definitive cure has ever been found. Perhaps a new insight into the effectiveness of …
definitive cure has ever been found. Perhaps a new insight into the effectiveness of …
Association of single-nucleotide polymorphisms in capecitabine bioactivation pathway with adjuvant therapy safety in colorectal cancer patients
Y Cura, A Sánchez-Martín, N Márquez-Pete… - Pharmaceutics, 2023 - mdpi.com
Capecitabine, an oral prodrug of 5-fluorouracil (5-FU), is part of the standard treatment of
colorectal cancer (CRC). Severe adverse dose limiting reactions that impair treatment safety …
colorectal cancer (CRC). Severe adverse dose limiting reactions that impair treatment safety …
Cost–effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK
R Koleva-Kolarova, H Vellekoop, S Huygens… - Personalized …, 2023 - Taylor & Francis
The aim of this study was to evaluate the cost–effectiveness of ToxNav©, a multivariant
genetic test, to screen for DPYD followed by personalized chemotherapy dosing for …
genetic test, to screen for DPYD followed by personalized chemotherapy dosing for …
Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer
ADM Knudsen, MW Modvig, M Vogsen, AR Kodahl - Medical Oncology, 2024 - Springer
This study aimed to evaluate the efficacy of capecitabine monotherapy for patients with
human epidermal growth factor receptor-2 (HER2) normal metastatic breast cancer (MBC) …
human epidermal growth factor receptor-2 (HER2) normal metastatic breast cancer (MBC) …
A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer
M Yan, P Yuan, Q Ouyang, Y Cheng… - Therapeutic …, 2022 - journals.sagepub.com
Background: Since lobaplatin (LBP) has been approved to treat metastatic breast cancer in
China, this study aimed to evaluate the safety and efficacy of LBP-based chemotherapy in …
China, this study aimed to evaluate the safety and efficacy of LBP-based chemotherapy in …
[HTML][HTML] Capecitabine monotherapy as first-line treatment in advanced HER2-normal breast cancer–a nationwide, retrospective study
Background and purpose Capecitabine can be used as first-line treatment for advanced
breast cancer. However, real-world data on efficacy of capecitabine in this setting is sparse …
breast cancer. However, real-world data on efficacy of capecitabine in this setting is sparse …
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)
G Rinnerthaler, SP Gampenrieder… - Therapeutic …, 2021 - journals.sagepub.com
Background: Bendamustine, a medication approved for the treatment of indolent non-
Hodgkin lymphoma, has already shown anticancer activity in metastatic breast cancer …
Hodgkin lymphoma, has already shown anticancer activity in metastatic breast cancer …
Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients
YA Cura Cuevas, A Sánchez Martín, N Márquez Pete… - 2023 - digibug.ugr.es
Capecitabine, an oral prodrug of 5-fluorouracil (5-FU), is part of the standard treatment of
colorectal cancer (CRC). Severe adverse dose limiting reactions that impair treatment safety …
colorectal cancer (CRC). Severe adverse dose limiting reactions that impair treatment safety …